MedTrace Logo

The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis

NCT00484263 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-06-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether the daily inhalation of nebulised hypertonic saline (6%) will decrease the incidence of pulmonary exacerbations and increase the quality of life for people with non cystic fibrosis bronchiectasis.

Conditions

Interventions

DRUG

Hypertonic saline 6% -

Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months

Sponsors & Collaborators

  • The Alfred

    lead OTHER

Principal Investigators

  • Anne Holland, PhD, BAppSc · The Alfred

  • Caroline H Nicolson, MPhysio · The Alfred

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484263 on ClinicalTrials.gov